Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Applications Concerning Specific Inihibitors and Therapeutic Agents for Botulinum Toxin B and Tetanus Neurotoxins

---
identifier: "/us/fr/02-19712"
source: "fr"
legal_status: "authoritative_unofficial"
title: "Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Applications Concerning Specific Inihibitors and Therapeutic Agents for Botulinum Toxin B and Tetanus Neurotoxins"
title_number: 0
title_name: "Federal Register"
section_number: "02-19712"
section_name: "Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Applications Concerning Specific Inihibitors and Therapeutic Agents for Botulinum Toxin B and Tetanus Neurotoxins"
positive_law: false
currency: "2002-08-05"
last_updated: "2002-08-05"
format_version: "1.1.0"
generator: "[email protected]"
agency: "Defense Department"
document_number: "02-19712"
document_type: "notice"
publication_date: "2002-08-05"
agencies:
  - "Defense Department"
  - "Army Department"
fr_citation: "67 FR 50652"
fr_volume: 67
fr_action: "Notice."
---


#  Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Patent Applications Concerning Specific Inihibitors and Therapeutic Agents for Botulinum Toxin B and Tetanus Neurotoxins

**AGENCY:**

Department of the Army, DOD.

**ACTION:**

Notice.

**SUMMARY:**

In accordance with 37 CFR 404.6 and 404.7, announcement is made of the availability for licensing of the related U.S. patent applications concerning “Specific Inhibitors and therapeutic Agents for Botulinum Toxin B and Tetanus Neurotoxins” listed below. The United States Government, as represented by the Secretary of the Army, has rights in these inventions. Foreign rights are also available.

**ADDRESSES:**

Commander, U.S. Army Medical Research and Materiel Command, ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, Frederick, MD 1702-5012.

**FOR FURTHER INFORMATION CONTACT:**

For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul Mele, Office of Research & Technology Assessment, (301) 619-6664, bh at telefax (301) 619-5034.

**SUPPLEMENTARY INFORMATION:**

The following patents are available for licensing:

(1) *U.S. Patent Application No.:* 09/570,022.

*Filed:* May 12, 2000.

*Title:* Previns as Specific Inhibitors and Therapeutic Agents for Botulinum

Toxin B and Tetanus Neurotoxins.

*Supplementary Information:* The compounds of the invention may be used as molecular building blocks to create compounds that are optimized for inhibiting the protease activity of Botulinum B and tetanus toxins. Foreign rights (PCT/US00/13215) are also available.

(2) *U.S. Patent Application No.:* 09/570,023.

*Filed:* May 12, 2000.

*Title:* Buforin I as a Specific Inhibitor and Therapeutic Agent for Botulinum Toxin B and Tetanus Neurotoxins.

*Supplementary Information:* The compounds of the invention may be used to inhibit the protease activity of Botulinum B and tetanus toxins. . Foreign rights (PCT/US00/12909) are also available.

(3) *U.S. Patent Application No.:* 09/979,101.

*Filed:* November 19, 2001.

*Title:* Previns as Specific Inhibitors and Therapeutic Agents for Botulinum Toxin B and Tetanus Neurotoxins.

*Supplementary Information:* The compounds of the invention may be used as molecular building blocks to create compounds that are optimized for inhibiting the protease activity of Botulinum B and tetanus toxins. Foreign rights (PCT/US00/13215) are also available.

Luz D. Ortiz,

Army Federal Register Liaison Officer.